In a retrospective analysis of 462 comorbid PTSD and MDD patients across 11 sites, Deep TMS delivered an 83.5% response rate with a mean 52% reduction in PTSD symptoms. The study also showed a 66.6% response rate, 27.3% remission, and 50% mean reduction in depression scores, highlighting market expansion potential.
The retrospective real-world analysis evaluated 462 individuals diagnosed with both PTSD and major depressive disorder at 11 treatment sites who completed at least 20 Deep TMS sessions using BrainsWay’s H1 or H7 coils. Efficacy was measured via changes in PTSD Checklist (PCL-5) and Patient Health Questionnaire-9 (PHQ-9) scores pre- and post-treatment.
The study found an 83.5% response rate defined as ≥50% reduction in PTSD symptoms with a mean 52% decrease in PCL-5 scores. Depression outcomes showed a 66.6% response rate, a 27.3% remission rate and an average 50% reduction in PHQ-9 scores.
This represents the largest real-world dataset for Deep TMS in comorbid PTSD and MDD, underscoring BrainsWay’s potential to extend its three FDA-cleared indications and capture new treatment markets. Robust clinical evidence could support broader adoption by providers and payers, driving future revenue growth.
Deep TMS remains unapproved by the FDA for PTSD and comorbid PTSD/MDD treatment, and these findings are pending peer review. BrainsWay plans further controlled trials and stakeholder engagement to pursue label expansion and reimbursement coverage.
